CICC Securities: Maintains Outperform Rating on WuXi Biologics (02269.HK), raises target price to HK$36.

Wisdom Financial News APP has learned that CICC released a research report stating that due to the smooth progress of the project of WuXi Biologics (02269.HK) and the improvement in operational efficiency, the 2025/2026 net profit forecast was raised by 5.5%/1.6% to 42.1/47.1 billion yuan, and the 2025/2026 adjusted profit forecast was raised by 2.5%/4.1% to 51.1/55.8 billion yuan. The industry rating is maintained as outperforming, with the current stock price corresponding to a 2025/2026 adjusted P/E of 21.7x/19.6x. Due to the recent upward shift in the valuation center of the pharmaceutical sector, the target price was raised by 10.8% to 36 Hong Kong dollars, corresponding to a 2025/2026 adjusted P/E of 26.3x/23.7x, with a 20.9% upside potential from the current stock price.